Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Current Assets (2023 - 2025)

Telix Pharmaceuticals (TLX) posted Current Assets of $330.3 million for Q4 2025, down 45.02% on a QoQ basis from $600.7 million in Q4 2024, and down 45.02% year-over-year from $600.7 million in Q4 2024.

Telix Pharmaceuticals (TLX) has 3 years of Current Assets data on file, last reported at $330.3 million in Q4 2025.

  • In Q4 2025, Current Assets fell 45.02% year-over-year to $330.3 million; the TTM figure through Dec 2025 stood at $330.3 million (down 45.02% YoY), while the FY2025 annual figure was $330.3 million, down 42.07% from the prior year.
  • Current Assets eased to $330.3 million in Q4 2025, from $600.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $600.7 million in Q4 2024 and bottomed at $151.4 million in Q4 2023.
  • A 3-year average of $360.8 million and a median of $330.3 million in 2025 frame the typical range for Current Assets.
  • Annual changes were most pronounced in 2024 — Current Assets surged 296.87% — and 2025, when it sank 45.02%.
  • Year by year, Current Assets stood at $151.4 million in 2023, then surged by 296.87% to $600.7 million in 2024, then sank by 45.02% to $330.3 million in 2025.
  • The last three Current Assets figures came in at $330.3 million (Q4 2025), $600.7 million (Q4 2024), and $151.4 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Assets (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 10.37 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 37.31 Mn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 1.25 Bn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 73.04 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 3.59 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 11.73 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 18.21 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 4.22 Bn
10 Telix Pharmaceuticals 4.52 Bn 4.38 Bn - 330.28 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 330.28 Mn
Dec 31, 2024 600.70 Mn
Dec 31, 2023 151.36 Mn